Who are SP + amodiaquine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sulfadoxine pyrimethamine (SP), Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin, Coartem, Coartem, Qualaquin, Malarone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sp-amodiaquine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

SP + amodiaquine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SP + amodiaquine (SP + amodiaquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial. Area: Infectious Diseases.

phase 3 Antimalarial Dihydropteroate synthase, Dihydrofolate reductase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

SP + amodiaquine (SP + amodiaquine) — London School of Hygiene and Tropical Medicine. Sulfadoxine and pyrimethamine work by inhibiting dihydropteroate synthase and dihydrofolate reductase, respectively, disrupting folic acid synthesis in Plasmodium parasites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SP + amodiaquine TARGET	SP + amodiaquine	London School of Hygiene and Tropical Medicine	phase 3	Antimalarial	Dihydropteroate synthase, Dihydrofolate reductase
Sulfadoxine pyrimethamine (SP)	Sulfadoxine pyrimethamine (SP)	Menzies School of Health Research	phase 3	Antibiotic	Dihydropteroate synthase, Dihydrofolate reductase
Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin	Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin	London School of Hygiene and Tropical Medicine	phase 3	Antimalarial	Dihydropteroate synthase, Dihydrofolate reductase, Heme detoxification pathway
Coartem	ARTEMETHER		marketed	Antimalarial [EPC]		2009-01-01
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Qualaquin	QUININE	Sun Pharm Industries	marketed	Antimalarial	Sodium channel alpha subunits; brain (Types I, II, III)	2005-01-01
Malarone	PROGUANIL	GSK	marketed	Antimalarial [EPC]		2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial class)

London School of Hygiene and Tropical Medicine · 6 drugs in this class
Sanofi · 3 drugs in this class
Epicentre · 2 drugs in this class
University of Oxford · 2 drugs in this class
· 2 drugs in this class
Frantz Viral Therapeutics, LLC · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Institut de Recherche pour le Developpement · 1 drug in this class
Centre de Recherche Médicale de Lambaréné · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SP + amodiaquine — Competitive Intelligence Brief. https://druglandscape.com/ci/sp-amodiaquine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab